Stockholm, October 11, 2016 — Nasdaq (Nasdaq: NDAQ) announces that the trading in InDex Pharmaceuticals Holding AB’s shares (short name: INDEX) commenced today on Nasdaq First North in Stockholm. InDex Pharmaceuticals belongs to the health care sector and is the 60 th company to be admitted to trading on Nasdaq’s Nordic markets* in 2016.
InDex Pharmaceuticals is a drug development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. Its lead drug candidate, cobitolimod, is in late stage clinical development for the treatment of ulcerative colitis, a debilitating chronic inflammatory bowel disease. A phase IIb clinical study is planned to start in the first half of 2017 with the goal to optimize the treatment with cobitolimod. InDex Pharmaceuticals is located at the Karolinska Institute Science Park in Stockholm, Sweden. For more information, please visit www.indexpharma.com .
“This is a very special day for InDex Pharmaceuticals,” said Peter Zerhouni, CEO of InDex Pharmaceuticals. “Our IPO resulted in some 5,000 new shareholders and proceeds of SEK 250 million before transaction costs. We will now focus on taking our lead drug candidate cobitolimod through the next value increasing phase.”
“We welcome InDex Pharmaceuticals to Nasdaq First North,” said Adam Kostyál, senior vice president and head of European listings at Nasdaq. “We continue to see a strong inflow of health care companies leveraging First North as a platform for future growth, and we look forward to supporting InDex Pharmaceuticals with the visibility and investor exposure that comes with a First North listing.”
InDex Pharmaceuticals has appointed Redeye AB as the Certified Adviser.
*Main markets and Nasdaq First North at Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland and Nasdaq Stockholm.
About Nasdaq First North
Nasdaq First North is regulated as a multilateral trading facility, operated by the different exchanges within Nasdaq Nordic (Nasdaq First North Denmark is regulated as an alternative marketplace). It does not have the legal status as an EU-regulated market. Companies at Nasdaq First North are subject to the rules of Nasdaq First North and not the legal requirements for admission to trading on a regulated market. The risk in such an investment may be higher than on the main market.
About Nasdaq Nasdaq (Nasdaq: NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,700 listed companies with a market value of over $9.3 trillion and nearly 18,000 corporate clients. To learn more, visit nasdaq.com/ambition or business.nasdaq.com .
Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland, Nasdaq Riga, Nasdaq Stockholm, Nasdaq Tallinn, Nasdaq Vilnius, Nasdaq Clearing and Nasdaq Broker Services are respectively brand names for the regulated markets of Nasdaq Copenhagen A/S, Nasdaq Helsinki Ltd., Nasdaq Iceland hf., Nasdaq Riga, AS, Nasdaq Stockholm AB, Nasdaq Tallinn AS, AB Nasdaq Vilnius, Nasdaq Clearing AB and Nasdaq Broker Services AB. Nasdaq Nordic represents the common offering by Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland and Nasdaq Stockholm. Nasdaq Baltic represents the common offering by Nasdaq Tallinn, Nasdaq Riga and Nasdaq Vilnius.
Cautionary Note Regarding Forward-Looking Statements
The matters described herein contain forward-looking statements that are made under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about Nasdaq and its products and offerings. We caution that these statements are not guarantees of future performance. Actual results may differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements involve a number of risks, uncertainties or other factors beyond Nasdaq's control. These factors include, but are not limited to factors detailed in Nasdaq's annual report on Form 10-K, and periodic reports filed with the U.S. Securities and Exchange Commission. We undertake no obligation to release any revisions to any forward-looking statements.
| Media Relations Contact: Erik Granström +46 8 405 78 07 erik.granstrom@nasdaq.com |
